Revenue ₹4,389cr, EBITDA ₹865cr, reported profit ₹41cr
Sales grew but margin fell
Watch: Track operating leverage
Home / Research / Biocon Limited
Revenue ₹4,389cr, EBITDA ₹865cr, reported profit ₹41cr
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=423fd217-56de-4b6e-a486-d176df038160.pdf
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=423fd217-56de-4b6e-a486-d176df038160.pdf
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=423fd217-56de-4b6e-a486-d176df038160.pdf
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=423fd217-56de-4b6e-a486-d176df038160.pdf
Sales grew but margin fell
Watch: Track operating leverage
Commercial conversion remains uneven
Watch: Watch biosimilars shipments
Margin compression offsets sales
Watch: Monitor launch contribution
Cost leverage is not yet visible
Watch: Track segment margins
Q2 financial decision snapshot: Consolidated revenue from operations ₹4,389 crore (+2% YoY), EBITDA ₹865 crore (−7%), EBITDA margin 20% (versus 22%), reported net profit ₹41 crore (versus ₹85 crore). H1 revenue from operations ₹8,725 crore (+6%), EBITDA ₹1,767 crore (approximately flat) and reported net profit ₹182 crore (versus ₹116 crore). WATCH: commercial biosimilars opportunity is material, but current reported margin and PBT deteriorated. [P]
Key takeaways
Management describes a transition from capital-intensive capability building toward commercial scale and cash generation, but that transition must be verified in the income and cash-flow statements, not inferred from an attractive pipeline alone. [P][T]
The WATCH stance reflects two competing facts: the biosimilars business has approved and launched products in several markets, while Syngene's services revenue and the group's margin remain under pressure. New insulin capacity, Yesafili and Yesintek commercial momentum, pertuzumab regulatory progress and emerging-market partnerships could create incremental revenue. Yet regulatory milestones, tender wins and contractual total value are not immediate cash earnings. [P]
No fair-value target is asserted because this issuer-source brief does not have a complete dated share-price, net-debt, minority-interest and cash-flow bridge. Biocon's consolidated structure matters: biosimilars, generics and Syngene services differ in ownership, margin, R&D spending and capital intensity. Investors should not apply a single peak-growth multiple to all segments without reconciling those differences. [P]
Key takeaways
[P]
Q2 EBITDA was ₹865 crore versus ₹928 crore in Q2 FY26 and ₹902 crore in Q1 FY27. Profit before tax before exceptional items was ₹62 crore versus ₹183 crore a year earlier, a 66% decline. Net profit before exceptional items was ₹44 crore versus ₹92 crore, while reported net profit was ₹41 crore versus ₹85 crore.
The current-quarter net exceptional item after tax and non-controlling interests was a negative ₹3 crore. These distinctions matter: a reported profit of ₹41 crore cannot be replaced by a pre-exceptional ₹44 crore without clear labeling.
[P]
H1 FY27 operating revenue was ₹8,725 crore versus ₹8,237 crore, up 6%. EBITDA was ₹1,767 crore versus ₹1,774 crore, approximately unchanged, with a margin of 20% versus 22%. H1 PBT before exceptional items was ₹203 crore versus ₹297 crore, down 32%.
Yet reported net profit was ₹182 crore versus ₹116 crore, up 57%, while pre-exceptional net profit was ₹189 crore versus ₹133 crore. The divergence between PBT and net-profit growth requires careful review of tax, minority interests and exceptional adjustments rather than a simplistic conclusion that underlying profitability accelerated.
[P]
R&D expense on the presentation's net definition was ₹237 crore in Q2 versus ₹251 crore a year earlier and ₹477 crore in H1 versus ₹455 crore. The company also describes R&D as 7% of revenue excluding Syngene. This denominator is different from consolidated revenue, so that percentage should not be multiplied by the full group revenue to manufacture a spending figure. [P]
Key takeaways
The H1 biosimilars business generated ₹5,664 crore revenue versus ₹5,179 crore, and EBITDA of ₹1,351 crore versus ₹1,331 crore; the margin slipped from 26% to 24%. [P]
The biologics portfolio includes Ogivri and Fulphila, which management said retained strong positions, Yesintek with growing access, and Yesafili with encouraging US launch progress. European launches of ustekinumab, denosumab and aflibercept broaden the portfolio.
Around twenty tender awards across several European countries represent potential access, not necessarily immediate recognized revenue. Market-share and payer-contract conversion should be measured in actual sales and collections.
[P][T]
Generics revenue rose to ₹774 crore from ₹701 crore in Q2, with EBITDA improving from ₹7 crore to ₹64 crore. That is a major improvement from a low prior-year base, with issuer-reported margin increasing from 1% to 8%.
H1 generics revenue rose to ₹1,536 crore from ₹1,332 crore, while EBITDA improved to ₹120 crore from a loss of ₹28 crore. Management cited capacity utilization, productivity, liraglutide and complex formulations.
The presentation flags a reclassification of common-utility cross charges in the prior-year generics comparator; a careful analyst should preserve that basis rather than claim pure like-for-like cost reduction. [P]
Services, principally Syngene, generated Q2 revenue of ₹833 crore versus ₹911 crore a year earlier, down 9%, although it improved 13% sequentially from ₹736 crore. H1 services revenue was ₹1,569 crore versus ₹1,785 crore, down 12%. A sequential recovery is encouraging but does not cancel the annual decline. CDMO demand, project conversion, client spending and capacity utilization remain separate drivers from biosimilar tender wins. [P]
Key takeaways
The expectation of a stronger second half is management outlook, not yet a reported result. [P][T]
Pertuzumab illustrates the difference between regulatory progress and commercial realization. Management cited a positive CHMP opinion, a Genentech settlement and a ten-year Brazil partnership with a stated US$400 million total contract value. The contract value spans years and must not be recognized as Q2 revenue or treated as a guaranteed present-value cash flow. Commercialization depends on launch timing, actual demand, tender participation and contract economics. [P]
The presentation also references a Biomm partnership in Brazil related to semaglutide and thirteen emerging-market launches across regions. These broaden opportunity but may require local approvals, pricing negotiations, manufacturing scale and distribution investment. In North America, Yesafili contract wins and Yesintek access are important, yet the next call should identify net sales growth, margin and collection rather than count contracts alone. [P]
The earnings-call management team includes the group chairperson, CEO, CFO, business and commercial executives and Syngene leadership. Investors should press for an explicit bridge between biosimilars shipment timing and recognized revenue, explain the decline in segment EBITDA margin, and reconcile the services slowdown with utilization and corrective actions. A higher H2 contribution is plausible but not proved until reported figures show it. [T]
Key takeaways
Group EBITDA of ₹865 crore is not equivalent to cash generated from operations. [P][T]
The capital question is whether the expanded biosimilars platform can increase asset turns and profit without matching increases in fixed costs and working capital. New insulin capacity may improve supply reliability and volume, but the payback depends on utilization, yield, pricing and cash collection. Generics productivity is encouraging because EBITDA rose sharply on a relatively modest revenue increase; services utilization remains a counterweight. [P]
R&D net spending of ₹237 crore in Q2 and ₹477 crore in H1 should be evaluated as part of a multiyear product-development cycle. Regulatory approvals can create economic options, but clinical, legal, manufacturing and launch costs may precede returns.
Tender awards and the Brazil contract's total value are not cash already received. An investor should obtain cash from operations, capex, acquisitions, lease and debt movements and a segment-level capital return bridge before assigning a premium valuation to the pipeline.
[P]
The next statutory review should distinguish operating cash from financing inflows and from any asset sale, capital raising or working-capital release. The objective is sustained cash conversion after launch spending. An apparently improving reported net profit can still coincide with weak PBT or cash flow, as the current H1 divergence illustrates. [P]
Key takeaways
A sustained increase in EBITDA margin above the Q2 20% baseline accompanied by improved PBT and cash generation would support this case. [P][T]
The base case assumes continued biosimilar portfolio expansion but uneven recognition of shipments and pricing, while services recover gradually and generics improve from a low base. The group may continue growing revenue modestly while high R&D, depreciation and operating expenses limit consolidated PBT. This case recognizes that segment mix can move favorably without immediate group-level earnings acceleration. [P]
The adverse case involves delayed biosimilar launches, payer and tender pressure, regulatory setbacks, slower insulin capacity utilization, Syngene project weakness or high capital costs. Biosimilars' Q2 EBITDA margin decline from 25% to 22% and services' 9% annual revenue decline are observable warning signs. Persistent group PBT weakness despite commercial milestones would undermine the inflection thesis. [P]
Falsifiers are explicit: failure of new products to generate recognized sales, continued biosimilars margin erosion, further services decline and poor cash conversion after capacity expansion. Conversely, sustained growth in actual biosimilar shipments, recovering segment EBITDA, services stabilization and cash earnings would validate the investment phase. No scenario probabilities, share prices or terminal multiples are invented. [P]
Key takeaways
Follow H1 EBITDA margin of 20% against the prior year's 22%, and do not interpret H1 net-profit growth alone as an operating recovery. [P]
For biosimilars, track ₹2,809 crore Q2 revenue and ₹623 crore EBITDA, along with Yesafili US launch sales, Yesintek payer access, European tender conversion, insulin capacity utilization and pertuzumab commercial timing. For generics, monitor whether ₹64 crore Q2 EBITDA and 8% margin persist as the base normalizes. For services, track recovery from ₹833 crore Q2 revenue and whether sequential growth is followed by year-on-year improvement. [P]
Request management's reconciliation of shipment timing, actual versus contracted Brazil revenue, Syngene utilization and the cash requirements of biosimilar launches. Obtain statutory cash flow, capex and debt before assigning incremental value to pipeline products. Raise conviction only when revenue, EBITDA, PBT and cash improve together; reduce conviction if product milestones accumulate without profitable sales. [T]
A market-based entry or exit plan needs separately verified price, valuation, financing and risk information. This report is a source-backed quarterly monitoring framework, not a stock-price target or a guarantee of returns. [P]
[P] issuer document, Biocon Q2 FY27 earnings presentation dated 4 November 2026: https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=423fd217-56de-4b6e-a486-d176df038160.pdf . [T] issuer document, call held 4 November 2026, filed 11 November: https://nsearchives.nseindia.com/corporate/Bioconlimited_11112026231520_Transcript_Earnings_Call.pdf .
All reported financial figures are ₹crore and refer to issuer-specified reporting bases. Pipeline ambitions, regulatory approvals, contract values and management guidance are not booked profits. This is an issuer-source brief with explicit limitations, not an independent audit or valuation certification.
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=423fd217-56de-4b6e-a486-d176df038160.pdf
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=423fd217-56de-4b6e-a486-d176df038160.pdf
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=423fd217-56de-4b6e-a486-d176df038160.pdf
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=423fd217-56de-4b6e-a486-d176df038160.pdf
This is dated research, not a live market quote. Scenarios and historical performance are not guarantees.